RE:Trends to support healthcare M&A in 2023: Thoughfuf planningThe long-term underlying drivers of M&A in healthcare remain strong with Big Pharma companies actively returning to M&A in the near future, given their substantial cash positions and search for more growth. Active pharma companies have proactively identifed the therapeutic areas that they believe will generate future growth for their company and are expected to move decisively.
Additionally, Big Pharma companies in Europe will turn to M&A to enter or double down on specialty drugs and rare diseases, to perform earlier phase 2 and phase 3 trials, and to speed up expansion in the US, which makes ONCY and attractive target for both European and US Big Pharma companies.